Go or no go? Big decisions loom for Bristol and Sanofi

The most eagerly awaited regulatory event of November is the advisory committee meeting for Biogen's Alzheimer's candidate aducanumab, but there are plenty of other projects awaiting US FDA approval decisions too.

The biggest is Bristol Myers Squibb’s Car-T candidate lisocabtagene maraleucel, and the verdict is one component that will determine whether holders of a contingent value right receive a payout. Meanwhile, Sanofi and Y-mabs are set to hear about rare disease assets.